Ron van Schaik

Ron van Schaik is a Full Professor at Erasmus MC in the Department of Clinical Chemistry, where he leads research at the intersection of pharmacogenetics, pharmacokinetics, and clinical biochemistry. His work emphasizes genotype-guided drug therapy and personalized dosing strategies across multiple therapeutic areas.

His research interests focus on pharmacogenetics and personalized medicine, particularly in optimizing drug therapy through genetic and metabolic profiling. Key areas include CYP2D6 and CYP3A4-mediated metabolism, DPYD deficiency screening for fluoropyrimidines, and genotype-based dosing in oncology, transplantation, and cardiology. His work bridges laboratory science with clinical implementation, aiming to improve drug safety and efficacy.

The recent articles highlight a consistent trend toward precision dosing and clinical translation of pharmacogenomics. Topics span from tacrolimus dosing in transplant patients to uracil-guided fluoropyrimidine therapy, genotype-based asthma treatment, and drug-drug interactions involving semaglutide and targeted cancer therapies. These reflect a strong commitment to evidence-based, individualized treatment protocols.

Scientific contributions and collaborations:

• Active in multi-center clinical trials such as the Alpe2U study
• Collaborates widely across oncology, pediatrics, cardiology, and pharmacology
• Research cited in high-impact journals including European Journal of Cancer, Clinical Pharmacokinetics, and Cancer Communications

He has supervised multiple research projects, as indicated by supervised work records, and is likely involved in major grant-funded initiatives, though specific grants are not listed. His work often involves interdisciplinary teams and translational research frameworks.

Ron van Schaik is part of a broad research network at Erasmus MC, contributing to the Clinical Chemistry department’s leadership in pharmacogenomic testing and implementation. His research group collaborates with national and international partners in pharmacology, genetics, and clinical medicine to advance precision medicine.